BrainsWay

BrainsWay is a commercial-stage medical device company with a mission to boldly advance neuroscience to improve health and transform lives. Its core achievement is the development and FDA clearance of its Deep TMS platform for multiple psychiatric indications, establishing it as a leader in noninvasive neuromodulation. The company's strategy focuses on expanding its cleared indications, optimizing treatment protocols, and growing its global installed base through direct sales and strategic partnerships. BrainsWay leverages a robust body of clinical evidence to drive adoption among providers and payers.

Proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform utilizing patented H-Coils to noninvasively stimulate deeper and broader brain structures for treating mental health and addiction disorders.

BrainsWay competes with first-generation TMS companies (e.g., Neuronetics), ECT, ketamine, and pharmaceuticals. Its primary advantages are deeper stimulation, FDA clearances for OCD and smoking addiction, and a strong patent portfolio, though it faces constant innovation pressure from new neuromodulation technologies.